middle.news
How Is Recce Pharmaceuticals Advancing Its Lead Drug Amid Rising Losses?
4:45am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Is Recce Pharmaceuticals Advancing Its Lead Drug Amid Rising Losses?
4:45am on Saturday 30th of August, 2025 AEST
Key Points
21% increase in net loss to $21.4 million due to higher R&D expenditure
Regulatory approvals granted for Phase 3 clinical trials of RECCE® 327 Topical Gel in Indonesia
Positive Phase 2 clinical trial results with high patient response rates
Raised over A$28 million through placements, entitlement offers, and debt facilities
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE